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567paper’s Figure 3B. Rest Pd/Pa offers the same diagnostic perfor-
mance as iFR compared with FFR.
Furthermore, the reproducibility claim by Dr. Sen and colleagues
regarding “lower-than-expected agreement in FFR” contradicts the
published literature. VERIFY (VERiﬁcation of Instantaneous
Wave-Free Ratio and Fractional Flow Reserve for the Assessment of
Coronary Artery Stenosis Severity in EverydaY Practice) demon-
strated 95% limits of agreement for repeated FFR measurements of
0.04, narrower than the wider 0.07 variability in iFR (3).
We emphasize that their table does not appear in any of our
publications, abstracts, or conference presentations. At best, the
table constitutes misattribution. Worryingly, such misattribution in
their letter parallels that at their public, not peer-reviewed, website
(4) and conference presentations. Speciﬁcally, the quoted words
“are most accurately assessed” attributed to Gould do not appear in
this decades-old and apparently dogmatic paper (5), either exactly
or in spirit. We demand that Sen and colleagues constrain their
speculation to the literature as published.
Resting electrocardiography, echocardiography, and perfusion
imaging play key roles in daily cardiology practice. However, the
stress versions of these tests often prove more useful for triage to
invasive cardiac catheterization. Do Sen and colleagues only offer
“rest tests” to their patients instead of stress tests?
To answer the question posed in the title of their letter, we
agree that lower is not better–for diagnostic accuracy or patient
survival.Nils P. Johnson, MD, MS
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Levels in Heart Failure Patients
With Preserved and Reduced
Ejection Fraction
van Veldhuisen et al. (1) reported that B-type natriuretic peptide
(BNP) levels are lower in patients with heart failure with preserved
ejection fraction (HFPEF) than in patients with HF with reduced
left ventricular (LV) EF (40%) and that for a certain level of BNP
the prognosis in patients with HFPEF is as poor as in those with
reduced LVEF.
According to the European Society of Cardiology guidelines the
diagnosis of HFPEF requires 4 conditions: symptoms of HF,
typical signs of HF, normal or only mildly reduced LVEF with left
ventricle with normal dimensions, and relevant structural heart
disease (LV hypertrophy/left atrial enlargement) and/or diastolic
dysfunction. Importantly, the structural or functional abnormali-
ties are mostly assessed by echocardiography. Echocardiographic
measures such as increased left atrial volume index (volume >34
ml/m2), LV ﬁlling pressure, or abnormalities of the mitral inﬂow
pattern and tissue velocities are substantial evidence of the presence
of HFPEF (2).
In the current study systematic echocardiographic evaluations to
examine diastolic dysfunction were not performed. Nevertheless,
the authors still report that echocardiography was done in more
than 85% of their study population. Unfortunately, no echocar-
diographic parameters are shown. It would be valuable to also
provide information on the echocardiographic values that could
give further insight into the determinants of a high or low level of
BNP in patients with HFPEF.*Joost D. E. Haeck, MD, PhD
*Department of Cardiology
Academic Medical Center – University of Amsterdam
Meibergdreef 9
1100DD Amsterdam
the Netherlands
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Heart Fail 2012;14:803–69.ReplyWe thank Dr. Haeck for his comments on our study regarding the
use of echocardiography (1). The diagnosis of heart failure with
preserved ejection fraction (HFPEF) is difﬁcult, and requires 4
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568conditions: signs of HF, symptoms of HF, normal or only mildly
reduced left ventricular ejection fraction (LVEF), and evidence of
structural heart disease (i.e., left ventricular [LV] hypertrophy
and/or left atrial [LA] enlargement and/or diastolic dysfunction)
(2). However, older trials in HFPEF enrolled patients who had
signs and symptoms of HF (3) and a normal or near-normal LVEF
(4,5). In recent years, a requirement for additional echocardio-
graphic criteria has become common (2).
The present study (1) enrolled patients (between 2002 and 2005)
with moderate to severe HF after a hospitalization for HF who had
evidence of “structural heart disease” without further speciﬁcation
(6). Of the 615 patients, 155 patients had an LVEF >40%, and for
145 patients (93%), a baseline echocardiogram was available. A
“dilated” LA (as assessed by the attending cardiologist) was present
in 90 patients (62%). Median B-type natriuretic peptide (BNP)
(Q1 to Q3) level in patients with a dilated LA was 373 pg/ml
(range: 183–805 pg/ml) compared with a BNP level of 266 pg/ml
(range: 86–598 pg/ml) in patients without a dilated LA
(p¼ 0.068). The presence (or absence) of “diastolic dysfunction” was
recorded in only 123 patients, and BNP levels were not different
among groups. LV hypertrophy on echocardiography was not scored
in this study. Clearly, neither LA size nor diastolic function was
quantiﬁed, and there was no core laboratory for the echocardiograms.*Dirk J. van Veldhuisen, MD, PhD
Tiny Jaarsma, RN, PhD
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